annual cash & cash equivalents:
$304.96M+$111.45M(+57.59%)Summary
- As of today (June 30, 2025), INVA annual cash & cash equivalents is $304.96 million, with the most recent change of +$111.45 million (+57.59%) on December 31, 2024.
- During the last 3 years, INVA annual cash & cash equivalents has risen by +$103.44 million (+51.33%).
- INVA annual cash & cash equivalents is now at all-time high.
Performance
INVA Cash and cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly cash & cash equivalents:
$319.09M+$14.13M(+4.63%)Summary
- As of today (June 30, 2025), INVA quarterly cash & cash equivalents is $319.09 million, with the most recent change of +$14.13 million (+4.63%) on March 31, 2025.
- Over the past year, INVA quarterly cash & cash equivalents has increased by +$140.73 million (+78.91%).
- INVA quarterly cash & cash equivalents is now -33.41% below its all-time high of $479.19 million, reached on September 30, 2020.
Performance
INVA quarterly cash & cash equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Cash and cash equivalents Formula
Cash & Cash Equivalents = Cash + Short-Term Investments
INVA Cash and cash equivalents Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +57.6% | +78.9% |
| 3 y3 years | +51.3% | +47.2% |
| 5 y5 years | +9.7% | -9.3% |
INVA Cash and cash equivalents Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | +57.6% | at high | +121.5% |
| 5 y | 5-year | at high | +57.6% | -33.4% | +637.5% |
| alltime | all time | at high | +753.1% | -33.4% | +2129.8% |
INVA Cash and cash equivalents History
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2025 | - | $319.09M(+4.6%) |
| Dec 2024 | $304.96M(+57.6%) | $304.96M(+17.0%) |
| Sep 2024 | - | $260.63M(+20.1%) |
| Jun 2024 | - | $217.00M(+21.7%) |
| Mar 2024 | - | $178.36M(-7.8%) |
| Dec 2023 | $193.51M(-33.5%) | $193.51M(+7.5%) |
| Sep 2023 | - | $180.00M(+4.0%) |
| Jun 2023 | - | $173.03M(+20.1%) |
| Mar 2023 | - | $144.05M(-50.5%) |
| Dec 2022 | $291.05M(+44.4%) | $291.05M(-3.2%) |
| Sep 2022 | - | $300.79M(+6.1%) |
| Jun 2022 | - | $283.58M(+30.8%) |
| Mar 2022 | - | $216.80M(+7.6%) |
| Dec 2021 | $201.53M(-18.2%) | $201.53M(+49.2%) |
| Sep 2021 | - | $135.12M(+212.3%) |
| Jun 2021 | - | $43.27M(-84.7%) |
| Mar 2021 | - | $282.89M(+14.8%) |
| Dec 2020 | $246.49M(-11.4%) | $246.49M(-48.6%) |
| Sep 2020 | - | $479.19M(+16.0%) |
| Jun 2020 | - | $413.15M(+17.4%) |
| Mar 2020 | - | $351.98M(+26.6%) |
| Dec 2019 | $278.10M(+345.5%) | $278.10M(+60.8%) |
| Sep 2019 | - | $172.95M(+21.8%) |
| Jun 2019 | - | $141.95M(+117.9%) |
| Mar 2019 | - | $65.15M(+4.4%) |
| Dec 2018 | $62.42M(-14.9%) | $62.42M(+28.4%) |
| Sep 2018 | - | $48.62M(-44.3%) |
| Jun 2018 | - | $87.23M(+221.4%) |
| Mar 2018 | - | $27.14M(-63.0%) |
| Dec 2017 | $73.34M(-37.9%) | $73.34M(-47.0%) |
| Sep 2017 | - | $138.42M(+8.4%) |
| Jun 2017 | - | $127.63M(-20.1%) |
| Mar 2017 | - | $159.81M(+35.4%) |
| Dec 2016 | $118.02M(-25.9%) | $118.02M(+26.6%) |
| Sep 2016 | - | $93.19M(-17.5%) |
| Jun 2016 | - | $112.94M(-25.6%) |
| Mar 2016 | - | $151.78M(-4.7%) |
| Dec 2015 | $159.18M(+64.4%) | $159.18M(+102.1%) |
| Sep 2015 | - | $78.75M(-47.4%) |
| Jun 2015 | - | $149.58M(+5.9%) |
| Mar 2015 | - | $141.19M(+45.9%) |
| Dec 2014 | $96.80M | $96.80M(-19.0%) |
| Sep 2014 | - | $119.58M(-42.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Jun 2014 | - | $208.05M(+66.1%) |
| Mar 2014 | - | $125.28M(-12.7%) |
| Dec 2013 | $143.51M(+51.3%) | $143.51M(-16.5%) |
| Sep 2013 | - | $171.89M(-13.7%) |
| Jun 2013 | - | $199.24M(-25.1%) |
| Mar 2013 | - | $266.07M(+180.5%) |
| Dec 2012 | $94.85M(+111.8%) | $94.85M(-15.5%) |
| Sep 2012 | - | $112.23M(-30.3%) |
| Jun 2012 | - | $161.10M(+1025.8%) |
| Mar 2012 | - | $14.31M(-68.0%) |
| Dec 2011 | $44.78M(-72.6%) | $44.78M(-28.6%) |
| Sep 2011 | - | $62.74M(-30.8%) |
| Jun 2011 | - | $90.66M(-38.7%) |
| Mar 2011 | - | $147.87M(-9.5%) |
| Dec 2010 | $163.33M(+243.5%) | $163.33M(+158.8%) |
| Sep 2010 | - | $63.10M(-9.5%) |
| Jun 2010 | - | $69.72M(-36.6%) |
| Mar 2010 | - | $109.92M(+131.2%) |
| Dec 2009 | $47.54M(-48.5%) | $47.54M(-27.5%) |
| Sep 2009 | - | $65.59M(+7.4%) |
| Jun 2009 | - | $61.10M(-16.2%) |
| Mar 2009 | - | $72.92M(-21.0%) |
| Dec 2008 | $92.28M(+6.8%) | $92.28M(-28.4%) |
| Sep 2008 | - | $128.97M(+47.2%) |
| Jun 2008 | - | $87.61M(+7.8%) |
| Mar 2008 | - | $81.28M(-6.0%) |
| Dec 2007 | $86.43M(+19.4%) | $86.43M(+9.6%) |
| Sep 2007 | - | $78.86M(+73.1%) |
| Jun 2007 | - | $45.55M(-41.0%) |
| Mar 2007 | - | $77.15M(+6.6%) |
| Dec 2006 | $72.39M(+45.4%) | $72.39M(-15.6%) |
| Sep 2006 | - | $85.73M(+1.0%) |
| Jun 2006 | - | $84.90M(-18.0%) |
| Mar 2006 | - | $103.52M(+107.9%) |
| Dec 2005 | $49.79M(-50.9%) | $49.79M(+122.7%) |
| Sep 2005 | - | $22.36M(-65.0%) |
| Jun 2005 | - | $63.88M(-25.3%) |
| Mar 2005 | - | $85.50M(-15.7%) |
| Dec 2004 | $101.41M(+183.7%) | $101.41M(+166.8%) |
| Sep 2004 | - | $38.00M(-64.2%) |
| Jun 2004 | - | $106.29M |
| Dec 2003 | $35.75M(-67.1%) | - |
| Dec 2002 | $108.80M | - |
FAQ
- What is Innoviva annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Innoviva?
- What is Innoviva annual cash & cash equivalents year-on-year change?
- What is Innoviva quarterly cash & cash equivalents?
- What is the all time high quarterly cash & cash equivalents for Innoviva?
- What is Innoviva quarterly cash & cash equivalents year-on-year change?
What is Innoviva annual cash & cash equivalents?
The current annual cash & cash equivalents of INVA is $304.96M
What is the all time high annual cash & cash equivalents for Innoviva?
Innoviva all-time high annual cash & cash equivalents is $304.96M
What is Innoviva annual cash & cash equivalents year-on-year change?
Over the past year, INVA annual cash & cash equivalents has changed by +$111.45M (+57.59%)
What is Innoviva quarterly cash & cash equivalents?
The current quarterly cash & cash equivalents of INVA is $319.09M
What is the all time high quarterly cash & cash equivalents for Innoviva?
Innoviva all-time high quarterly cash & cash equivalents is $479.19M
What is Innoviva quarterly cash & cash equivalents year-on-year change?
Over the past year, INVA quarterly cash & cash equivalents has changed by +$140.73M (+78.91%)